• ALLOX is a spin-off from the Centre for Genomic Regulation in Barcelona, and is founded by the researchers Ben Lehner, Júlia Domingo, Pablo Baeza and Andre Faure.
• The company is developing a proprietary platform technology to design new drugs targeting protein allosteric sites to treat cancer and potentially many other diseases
• Sabadell Asabys II has backed the company and will join a future round involving local and international investors.

ALLOX, a techbio company developing a proprietary technology to design new drugs targeting allosteric sites within oncology and other diseases, announces its incorporation today, as well as the successful closing of an undisclosed pre-seed financing from Asabys’ new fund Sabadell Asabys II.

Read the full press release from Asabys

ALLOX founders and investors